FDA OKs new Linzess dose for CIC patients

|About: Allergan plc (AGN)|By:, SA News Editor

The FDA approves a new 72 mcg dose of LINZESS (linaclotide) for the treatment of patients with chronic idiopathic constipation (CIC). The original approved dosage for CIC was 145 mcg. For IBS-C, it is 290 mcg.

Related tickers: (NYSE:AGN) (NASDAQ:IRWD)

Subscribe for full text news in your inbox